Skip to main content
BTI
NYSE Manufacturing

BAT H1 2026: Smokeless Hits 19.8% of Revenue, Adjusted EPS +5.9%, FII GLO Concluded

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Neutral
Importance info
7
Price
$63.37
Mkt Cap
$136.55B
52W Low
$49.88
52W High
$67.3
52W Position info
27% above low
Off High info
5.8% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BTI sits 27% above its 52-week low of $49.88.

Summary

BAT's H1 2026 results show Smokeless revenue reaching 19.8% of the total, with adjusted EPS up 5.9% at constant currencies. The FII GLO litigation concluded, releasing a £410M net credit, while the Fit2Win restructuring programme is on track.


Key Events · Earnings and Guidance · BTI

  • H1 2026 Results

    Revenue reached £12,235M, up 1.4% on a reported basis and 2.9% at constant currencies. Adjusted diluted EPS came in at 167.7p, a 5.9% constant-currency increase. New Categories revenue surged 18.0% at constant FX, with Modern Oral jumping 65.9% and Vapour rising 5.3%. Smokeless products now account for 19.8% of Group revenue.

  • FII GLO Litigation Concluded

    The Franked Investment Income Group Litigation Order has reached its conclusion, resulting in an adjusting net credit to finance costs of £315M and a tax credit of £95M recognised in H1 2026.

  • Fit2Win Restructuring Update

    Total expected one-off costs now stand at approximately £950M, comprising £330M in non-cash charges and £620M in cash outflows, with £370M recognised in H1 2026. The programme is expected to complete in 2027 and generate annualised cost efficiencies.

  • Share Buy-Back on Track

    In H1 2026, £649M of shares were repurchased, keeping the full-year £1.3B buy-back programme on schedule. A total of 14.6M ordinary shares were repurchased and cancelled during the period.


Analysis · BTI · Manufacturing

British American Tobacco's half-year results show accelerating New Categories growth, with Smokeless products now nearly a fifth of revenue. Adjusted diluted EPS rose 5.9% at constant currencies, driven by strong U.S. performance and Modern Oral. The conclusion of the long-running FII GLO litigation released a £410M net credit, while the Fit2Win restructuring programme is on track to deliver £950M in total one-off costs. The reaffirmed guidance and £1.3B buyback provide stability, but net debt remains elevated at £32.6B. The results are a mixed bag: operational momentum is solid, but litigation and restructuring noise cloud the bottom line.

At the time of this filing, BTI was trading at $63.37 on NYSE in the Manufacturing sector, with a market capitalization of approximately $136.5B. The 52-week trading range was $49.88 to $67.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BTI - Latest Insights

BTI
Jul 30, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $62.97
Real-time Price: $61.52 info
Change: -$1.45 (-2%) info
Market Cap: $136.55B info
BTI
Jul 01, 2026, 10:24 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $60.37
Real-time Price: $61.52 info
Change: +$1.15 (+2%) info
Market Cap: $136.55B info
BTI
Jun 02, 2026, 4:33 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $60.90
Real-time Price: $61.52 info
Change: +$0.620 (+1%) info
Market Cap: $136.55B info
BTI
May 01, 2026, 12:30 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $58.76
Real-time Price: $61.52 info
Change: +$2.76 (+5%) info
Market Cap: $136.55B info
BTI
Apr 09, 2026, 9:31 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $58.36
Real-time Price: $61.52 info
Change: +$3.16 (+5%) info
Market Cap: $136.55B info